Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL CELL ANALYSIS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE CELL ANALYSIS SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 SALES VOLUME DATA
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL CELL ANALYSIS MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7 INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8 COST ANALYSIS BREAKDOWN
9 TECHNONLOGY ROADMAP
10 INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 MERGERS AND ACQUISITIONS
10.8 FUTURE OUTLOOK
11 REGULATORY COMPLIANCE
11.1 REGULATORY AUTHORITIES
11.2 REGULATORY CLASSIFICATIONS
11.2.1 CLASS I
11.2.2 CLASS II
11.2.3 CLASS III
11.3 REGULATORY SUBMISSIONS
11.4 INTERNATIONAL HARMONIZATION
11.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
11.6 REGULATORY CHALLENGES AND STRATEGIES
12 PIPELINE ANALYSIS
12.1 CLINICAL TRIALS AND PHASE ANALYSIS
12.2 DRUG THERAPY PIPELINE
12.3 PHASE III CANDIDATES
12.4 PHASE II CANDIDATES
12.5 PHASE I CANDIDATES
12.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR CELL ANALYSIS MARKET
Company Name Product Name
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE CELL ANALYSIS MARKET
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved but Not Yet Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE FOR CELL ANALYSIS MARKET
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE FOR CELL ANALYSIS MARKET
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR CELL ANALYSIS MARKET
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
13 REIMBURSEMENT FRAMEWORK
14 OPPUTUNITY MAP ANALYSIS
15 VALUE CHAIN ANALYSIS
16 HEALTHCARE ECONOMY
16.1 HEALTHCARE EXPENDITURE
16.2 CAPITAL EXPENDITURE
16.3 CAPEX TRENDS
16.4 CAPEX ALLOCATION
16.5 FUNDING SOURCES
16.6 INDUSTRY BENCHMARKS
16.7 GDP RATION IN OVERALL GDP
16.8 HEALTHCARE SYSTEM STRUCTURE
16.9 GOVERNMENT POLICIES
16.1 ECONOMIC DEVELOPMENT
17 GLOBAL CELL ANALYSIS MARKET, BY PRODUCT
17.1 OVERVIEW
17.2 INSTRUMENTS
17.2.1 BY TYPE
17.2.1.1. PCR
17.2.1.1.1. DIGITAL PCR
17.2.1.1.2. REAL-TIME PCR
17.2.1.2. FLOW CYTOMETERS
17.2.1.2.1. CELL-BASED FLOW CYTOMETRY
17.2.1.2.2. BEAD-BASED FLOW CYTOMETRY
17.2.1.3. MICROSCOPES
17.2.1.3.1. OPTICAL
17.2.1.3.1.1 UPRIGHT
17.2.1.3.1.2 INVERTED
17.2.1.3.1.3 STEREOMICROSCOPES
17.2.1.3.1.4 PHASE CONTRAST
17.2.1.3.1.5 FLUORESCENCE
17.2.1.3.1.6 CONFOCAL SCANNING
17.2.1.3.1.7 NEAR FIELD SCANNING
17.2.1.3.1.8 OTHER OPTICAL MICROSCOPES
17.2.1.3.2. ELECTRON
17.2.1.3.2.1 SCANNING ELECTRON
17.2.1.3.2.2 TRANSMISSION
17.2.1.3.3. SCANNING PROBE
17.2.1.3.4. OTHERS
17.2.1.4. SPECTROPHOTOMETERS
17.2.1.4.1. MOLECULAR SPECTROMETRY
17.2.1.4.1.1 VISIBLE AND ULTRAVIOLET SPECTROSCOPY
17.2.1.4.1.2 INFRARED SPECTROSCOPY
17.2.1.4.1.3 NUCLEAR MAGNETIC RESONANCE (NMR) SPECTROSCOPY
17.2.1.4.1.4 OTHERS
17.2.1.4.2. MASS SPECTROMETRY (MS)
17.2.1.4.2.1 MALDI-TOF
17.2.1.4.2.2 TRIPLE QUADRUPOLE
17.2.1.4.2.3 QUADRUPOLE-TRAP
17.2.1.4.2.4 HYBRID LINEAR ION TRAP ORBITRAP
17.2.1.4.2.5 QUADRUPOLE-ORBITRAP
17.2.1.4.3. ATOMIC SPECTROMETRY
17.2.1.5. HEMOCYTOMETERS
17.2.1.5.1. DISPOSABLE
17.2.1.5.2. REUSABLE
17.2.1.6. CELL COUNTERS
17.2.1.7. CELL SORTER
17.2.1.7.1. MAGNETIC-ACTIVATED CELL SORTING (MACS) SYSTEM
17.2.1.7.2. OTHERS
17.2.1.8. MICROFLUIDIC DEVICES.
17.2.1.9. INCUBATORS
17.2.1.10. BIOSAFETY CABINETS
17.2.1.11. CENTRIFUGE
17.2.1.12. OTHERS
17.2.2 BY MODE
17.2.2.1. AUTOMATIC
17.2.2.2. MANUAL
17.2.3 BY MODALITY
17.2.3.1. BENCHTOP
17.2.3.2. PORTABLES
17.2.3.3. STANDALONE
17.2.3.4. OTHERS
17.3 CONSUMABLES
17.3.1 REAGENTS & KITS
17.3.2 STAINS & DYES
17.3.3 PROBES
17.3.4 BUFFERS & MEDIA
17.3.5 STANDARDS & CONTROLS
17.3.6 CELL DISSOCIATION REAGENTS
17.3.7 GLASS SLIDES AND COVERSLIPS.
17.3.8 MICROPLATES
17.3.9 BEADS
17.3.10 DISPOSABLES
17.3.11 OTHERS
18 GLOBAL CELL ANALYSIS MARKET, BY PROCESS
18.1 CELL IDENTIFICATION
18.2 CELL VIABILITY
18.3 CELL SIGNALLING PATHWAY/SIGNAL TRANSDUCTION
18.4 CELL PROLIFERATION
18.5 CELL COUNTING AND QUALITY CONTROL
18.6 CELL INTERACTION
18.7 CELL STRUCTURE STUDY
18.8 TARGET IDENTIFICATION AND VALIDATION
18.9 SINGLE-CELL ANALYSIS
18.1 OTHERS
19 GLOBAL CELL ANALYSIS MARKET, BY TECHNIQUE
19.1 OVERVIEW
19.2 NEXT-GENERATION SEQUENCING
19.2.1 WHOLE GENOME SEQUENCING
19.2.2 TARGETED SEQUENCING & RESEQUENCING
19.2.3 OTHERS
19.3 FLOW CYTOMETRY
19.4 POLYMERASE CHAIN REACTION
19.5 MICROSCOPY
19.6 SPECTROMETRY
19.7 MICROARRAY
19.8 OTHERS
20 GLOBAL CELL ANALYSIS MARKET, BY CELL TYPE
20.1 OVERVIEW
20.2 HUMAN CELLS
20.2.1 PRIMARY CELLS
20.2.2 STEM CELLS
20.2.3 DIFFERENTIATED CELLS
20.2.4 TUMOR CELLS
20.3 ANIMAL CELLS
20.3.1 PRIMARY CELLS
20.3.2 STEM CELLS
20.3.3 DIFFERENTIATED CELLS
20.3.4 TUMOR CELLS
20.4 MICROBIAL CELLS
20.4.1 PRIMARY CELLS
20.4.2 STEM CELLS
20.4.3 DIFFERENTIATED CELLS
20.4.4 TUMOR CELLS
20.5 PLANT CELLS
21 GLOBAL CELL ANALYSIS MARKET, BY APPLICATION
21.1 OVERVIEW
21.2 RESEARCH APPLICATIONS
21.2.1 BY TYPE
21.2.1.1. STEM CELL RESEARCH
21.2.1.2. CANCER RESEARCH
21.2.1.2.1. LUNG CANCER
21.2.1.2.2. STOMACH CANCER
21.2.1.2.3. COLORECTAL CANCER
21.2.1.2.4. BREAST CANCER
21.2.1.2.5. PROSTATE CANCER
21.2.1.2.6. LIVER CANCER
21.2.1.2.7. ESOPHAGUS CANCER
21.2.1.2.8. CERVICAL CANCER
21.2.1.2.9. KIDNEY CANCER
21.2.1.2.10. BLADDER CANCER
21.2.1.2.11. OTHERS
21.2.1.3. DRUG DISCOVERY & DEVELOPMENT
21.2.1.4. IMMUNOLOGY RESEARCH
21.2.1.5. NEUROBIOLOGY RESEARCH
21.2.1.6. CELL BIOLOGY RESEARCH
21.2.2 BY PRODUCT
21.2.2.1. INSTRUMENTS
21.2.2.2. CONSUMBALES
21.3 CLINICAL APPLICATIONS
21.3.1 BY TYPE
21.3.1.1. DISEASE DIAGNOSIS
21.3.1.2. HEMATOLOGY
21.3.1.3. ONCOLOGY
21.3.1.4. INFECTIOUS DISEASES
21.3.1.5. CARDIOLOGY
21.3.1.6. OTHERS
21.3.2 BY PRODUCT
21.3.2.1. INSTRUMENTS
21.3.2.2. CONSUMBALES
21.4 INDUSTRIAL APPLICATIONS
21.4.1 BY TYPE
21.4.1.1. BIOPROCESSING
21.4.1.2. QUALITY CONTROL
21.4.1.3. ENVIRONMENTAL TESTING
21.4.2 BY PRODUCT
21.4.2.1. INSTRUMENTS
21.4.2.2. CONSUMBALES
21.5 OTHERS
22 GLOBAL CELL ANALYSIS MARKET, BY END USER
22.1 OVERVIEW
22.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
22.2.1 BY TYPE
22.2.1.1. SMALL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
22.2.1.2. MEDIUM PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
22.2.1.3. ARGE PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
22.2.2 BY PRODUCT
22.2.2.1. INSTRUMENTS
22.2.2.2. CONSUMABLES
22.3 ACADEMIC & RESEARCH INSTITUTES
22.3.1 BY PRODUCT
22.3.1.1. INSTRUMENTS
22.3.1.2. CONSUMBALES
22.4 CONTRACT RESEARCH ORGANIZATIONS (CROS)
22.4.1 BY PRODUCT
22.4.1.1. INSTRUMENTS
22.4.1.2. CONSUMBALES
22.5 DIAGNOSTIC LABORATORIES
22.5.1 BY PRODUCT
22.5.1.1. INSTRUMENTS
22.5.1.2. CONSUMBALES
22.6 HOSPITALS & CLINICAL TESTING LABS
22.6.1 BY PRODUCT
22.6.1.1. INSTRUMENTS
22.6.1.2. CONSUMBALES
22.7 CELL BANKS & BIOREPOSITORIES
22.7.1 BY PRODUCT
22.7.1.1. INSTRUMENTS
22.7.1.2. CONSUMBALES
22.8 GOVERNMENT & REGULATORY AGENCIES
22.8.1 BY PRODUCT
22.8.1.1. INSTRUMENTS
22.8.1.2. CONSUMBALES
22.9 OTHERS
23 GLOBAL CELL ANALYSIS MARKET, BY SALES CHANNEL
23.1 OVERVIEW
23.2 DIRECT TENDER
23.3 RETAIL SALES
23.3.1 OFFLINE
23.3.2 ONLINE
23.4 OTHERS
24 GLOBAL CELL ANALYSIS MARKET, BY GEOGRAPHY
GLOBAL CELL ANALYSIS MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
24.1 NORTH AMERICA
24.1.1 U.S.
24.1.2 CANADA
24.1.3 MEXICO
24.2 EUROPE
24.2.1 GERMANY
24.2.2 FRANCE
24.2.3 U.K.
24.2.4 ITALY
24.2.5 SPAIN
24.2.6 RUSSIA
24.2.7 TURKEY
24.2.8 BELGIUM
24.2.9 NETHERLANDS
24.2.10 SWITZERLAND
24.2.11 REST OF EUROPE
24.3 ASIA-PACIFIC
24.3.1 JAPAN
24.3.2 CHINA
24.3.3 SOUTH KOREA
24.3.4 INDIA
24.3.5 AUSTRALIA
24.3.6 SINGAPORE
24.3.7 THAILAND
24.3.8 MALAYSIA
24.3.9 INDONESIA
24.3.10 PHILIPPINES
24.3.11 REST OF ASIA-PACIFIC
24.4 SOUTH AMERICA
24.4.1 BRAZIL
24.4.2 ARGENTINA
24.4.3 PERU
24.4.4 CHILE
24.4.5 COLOMBIA
24.4.6 VENEZUELA
24.4.7 REST OF SOUTH AMERICA
24.5 MIDDLE EAST AND AFRICA
24.5.1 SOUTH AFRICA
24.5.2 SAUDI ARABIA
24.5.3 UAE
24.5.4 EGYPT
24.5.5 ISRAEL
24.5.6 REST OF MIDDLE EAST AND AFRICA
24.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
25 GLOBAL CELL ANALYSIS MARKET, COMPANY LANDSCAPE
25.1 COMPANY SHARE ANALYSIS: GLOBAL
25.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
25.3 COMPANY SHARE ANALYSIS: EUROPE
25.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
25.5 MERGERS & ACQUISITIONS
25.6 NEW PRODUCT DEVELOPMENT & APPROVALS
25.7 EXPANSIONS
25.8 REGULATORY CHANGES
25.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
26 GLOBAL CELL ANALYSIS MARKET, SWOT AND DBMR ANALYSIS
27 GLOBAL CELL ANALYSIS MARKET, COMPANY PROFILE
27.1 THERMO FISHER SCIENTIFIC INC.
27.1.1 COMPANY OVERVIEW
27.1.2 REVENUE ANALYSIS
27.1.3 GEOGRAPHIC PRESENCE
27.1.4 PRODUCT PORTFOLIO
27.1.5 RECENT DEVELOPEMENTS
27.2 BECTON, DICKINSON AND COMPANY
27.2.1 COMPANY OVERVIEW
27.2.2 REVENUE ANALYSIS
27.2.3 GEOGRAPHIC PRESENCE
27.2.4 PRODUCT PORTFOLIO
27.2.5 RECENT DEVELOPEMENTS
27.3 DANAHER CORPORATION
27.3.1 COMPANY OVERVIEW
27.3.2 REVENUE ANALYSIS
27.3.3 GEOGRAPHIC PRESENCE
27.3.4 PRODUCT PORTFOLIO
27.3.5 RECENT DEVELOPEMENTS
27.4 MERCK KGAA
27.4.1 COMPANY OVERVIEW
27.4.2 REVENUE ANALYSIS
27.4.3 GEOGRAPHIC PRESENCE
27.4.4 PRODUCT PORTFOLIO
27.4.5 RECENT DEVELOPEMENTS
27.5 AGILENT TECHNOLOGIES, INC.
27.5.1 COMPANY OVERVIEW
27.5.2 REVENUE ANALYSIS
27.5.3 GEOGRAPHIC PRESENCE
27.5.4 PRODUCT PORTFOLIO
27.5.5 RECENT DEVELOPEMENTS
27.6 BIO-RAD LABORATORIES, INC.
27.6.1 COMPANY OVERVIEW
27.6.2 REVENUE ANALYSIS
27.6.3 GEOGRAPHIC PRESENCE
27.6.4 PRODUCT PORTFOLIO
27.6.5 RECENT DEVELOPEMENTS
27.7 PERKINELMER, INC.
27.7.1 COMPANY OVERVIEW
27.7.2 REVENUE ANALYSIS
27.7.3 GEOGRAPHIC PRESENCE
27.7.4 PRODUCT PORTFOLIO
27.7.5 RECENT DEVELOPEMENTS
27.8 GE HEALTHCARE
27.8.1 COMPANY OVERVIEW
27.8.2 REVENUE ANALYSIS
27.8.3 GEOGRAPHIC PRESENCE
27.8.4 PRODUCT PORTFOLIO
27.8.5 RECENT DEVELOPEMENTS
27.9 ILLUMINA, INC.
27.9.1 COMPANY OVERVIEW
27.9.2 REVENUE ANALYSIS
27.9.3 GEOGRAPHIC PRESENCE
27.9.4 PRODUCT PORTFOLIO
27.9.5 RECENT DEVELOPEMENTS
27.1 ROCHE DIAGNOSTICS
27.10.1 COMPANY OVERVIEW
27.10.2 REVENUE ANALYSIS
27.10.3 GEOGRAPHIC PRESENCE
27.10.4 PRODUCT PORTFOLIO
27.10.5 RECENT DEVELOPEMENTS
27.11 PROMEGA CORPORATION
27.11.1 COMPANY OVERVIEW
27.11.2 REVENUE ANALYSIS
27.11.3 GEOGRAPHIC PRESENCE
27.11.4 PRODUCT PORTFOLIO
27.11.5 RECENT DEVELOPEMENTS
27.12 ABCAM PLC
27.12.1 COMPANY OVERVIEW
27.12.2 REVENUE ANALYSIS
27.12.3 GEOGRAPHIC PRESENCE
27.12.4 PRODUCT PORTFOLIO
27.12.5 RECENT DEVELOPEMENTS
27.13 MILTENYI BIOTEC
27.13.1 COMPANY OVERVIEW
27.13.2 REVENUE ANALYSIS
27.13.3 GEOGRAPHIC PRESENCE
27.13.4 PRODUCT PORTFOLIO
27.13.5 RECENT DEVELOPEMENTS
27.14 SARTORIUS AG
27.14.1 COMPANY OVERVIEW
27.14.2 REVENUE ANALYSIS
27.14.3 GEOGRAPHIC PRESENCE
27.14.4 PRODUCT PORTFOLIO
27.14.5 RECENT DEVELOPEMENTS
27.15 TECAN GROUP LTD.
27.15.1 COMPANY OVERVIEW
27.15.2 REVENUE ANALYSIS
27.15.3 GEOGRAPHIC PRESENCE
27.15.4 PRODUCT PORTFOLIO
27.15.5 RECENT DEVELOPEMENTS
27.16 CELL SIGNALING TECHNOLOGY, INC.
27.16.1 COMPANY OVERVIEW
27.16.2 REVENUE ANALYSIS
27.16.3 GEOGRAPHIC PRESENCE
27.16.4 PRODUCT PORTFOLIO
27.16.5 RECENT DEVELOPEMENTS
27.17 SYSMEX CORPORATION
27.17.1 COMPANY OVERVIEW
27.17.2 REVENUE ANALYSIS
27.17.3 GEOGRAPHIC PRESENCE
27.17.4 PRODUCT PORTFOLIO
27.17.5 RECENT DEVELOPEMENTS
27.18 OLYMPUS CORPORATION
27.18.1 COMPANY OVERVIEW
27.18.2 REVENUE ANALYSIS
27.18.3 GEOGRAPHIC PRESENCE
27.18.4 PRODUCT PORTFOLIO
27.18.5 RECENT DEVELOPMENTS.
27.19 TAKARA BIO INC.
27.19.1 COMPANY OVERVIEW
27.19.2 REVENUE ANALYSIS
27.19.3 GEOGRAPHIC PRESENCE
27.19.4 PRODUCT PORTFOLIO
27.19.5 RECENT DEVELOPEMENTS
27.2 AXION BIOSYSTEMS
27.20.1 COMPANY OVERVIEW
27.20.2 REVENUE ANALYSIS
27.20.3 GEOGRAPHIC PRESENCE
27.20.4 PRODUCT PORTFOLIO
27.20.5 RECENT DEVELOPEMENTS
27.21 EPPENDORF AG
27.21.1 COMPANY OVERVIEW
27.21.2 REVENUE ANALYSIS
27.21.3 GEOGRAPHIC PRESENCE
27.21.4 PRODUCT PORTFOLIO
27.21.5 RECENT DEVELOPEMENTS
27.22 BRUKER CORPORATION
27.22.1 COMPANY OVERVIEW
27.22.2 REVENUE ANALYSIS
27.22.3 GEOGRAPHIC PRESENCE
27.22.4 PRODUCT PORTFOLIO
27.22.5 RECENT DEVELOPEMENTS
27.23 QIAGEN N.V.
27.23.1 COMPANY OVERVIEW
27.23.2 REVENUE ANALYSIS
27.23.3 GEOGRAPHIC PRESENCE
27.23.4 PRODUCT PORTFOLIO
27.23.5 RECENT DEVELOPEMENTS
27.24 FLUIDIGM CORPORATION
27.24.1 COMPANY OVERVIEW
27.24.2 REVENUE ANALYSIS
27.24.3 GEOGRAPHIC PRESENCE
27.24.4 PRODUCT PORTFOLIO
27.24.5 RECENT DEVELOPEMENTS
27.25 BIO-TECHNE CORPORATION
27.25.1 COMPANY OVERVIEW
27.25.2 REVENUE ANALYSIS
27.25.3 GEOGRAPHIC PRESENCE
27.25.4 PRODUCT PORTFOLIO
27.25.5 RECENT DEVELOPEMENTS
27.26 CHARLES RIVER LABORATORIES
27.26.1 COMPANY OVERVIEW
27.26.2 REVENUE ANALYSIS
27.26.3 GEOGRAPHIC PRESENCE
27.26.4 PRODUCT PORTFOLIO
27.26.5 RECENT DEVELOPEMENTS
27.27 LUMINEX CORPORATION
27.27.1 COMPANY OVERVIEW
27.27.2 REVENUE ANALYSIS
27.27.3 GEOGRAPHIC PRESENCE
27.27.4 PRODUCT PORTFOLIO
27.27.5 RECENT DEVELOPEMENTS
27.28 SONY BIOTECHNOLOGY INC.
27.28.1 COMPANY OVERVIEW
27.28.2 REVENUE ANALYSIS
27.28.3 GEOGRAPHIC PRESENCE
27.28.4 PRODUCT PORTFOLIO
27.28.5 RECENT DEVELOPEMENTS
28 CONCLUSION
29 QUESTIONNAIRE
30 ABOUT DATA BRIDGE MARKET RESEARCH
